← All trials
NCT04041674
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2019
- Primary completion
- Sep 30, 2021
- Completion date
- May 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 70
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Duke UniversityCollaborator
- Vanderbilt UniversityStudy chair
- University of RochesterStudy chair
- University of MarylandCollaborator
- University of WashingtonCollaborator
- GeoVax, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.